{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-22-000086","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2022-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.399790+00:00","generated_at":"2026-06-23T07:18:55.466558+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Context Therapeutics extends cash runway to Q1 2024, prioritizes key pipeline programs","bullets":["Cash runway extended to Q1 2024; deferring noncritical R&D and reducing overhead.","ONA-XR ELONA Phase 1b/2 trial with elacestrant for ER+/PR+/HER2- mBCa starts Q4 2022; data Q4 2023.","CLDN6xCD3 BsMAb candidate nomination Q4 2022; IND submission planned Q1 2024.","Preliminary data from ISTs: granulosa cell/endometrial cancer Nov 2022; breast cancer Dec 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-22-000086","json":"https://secwatch.observer/filing/0001842952-22-000086.json","markdown":"https://secwatch.observer/filing/0001842952-22-000086.md","text":"https://secwatch.observer/filing/0001842952-22-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000086/0001842952-22-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000086/cntx-20220927.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:18:55.466558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}